Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer
David A Cameron* and Steven Stein
Correspondence *National Cancer Research Network Co-ordinating Centre, 24 Hyde Terrace, Leeds LS2 9LN, UK
Email d.cameron@ncrn.org.uk
There are few treatment options for patients with metastatic HER2-positive breast cancer who are unresponsive to trastuzumab. The combination of lapatinib and capecitabine significantly prolongs time to disease progression in women previously treated with chemotherapy and trastuzumab for HER2-positive advanced disease. The rationale for using this combination and the promising activity of lapatinib in early trials of inflammatory breast cancer is highlighted.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitorOncogene Original Article
See all 14 matches for Research